RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
Trial details
- Registry ID
- NCT04616924
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Clarithromycin 158.3mg, Rifabutin 40mg and Clofazimine 13.3mg
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex DiseaseNCT04616924 | RedHill Biopharma Limited | Phase 3 | Terminated | 2023-08-28Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |